Free trade deals could endanger supplies of antiretrovirals by Indian producers
This article was originally published in Scrip
Executive Summary
An evolving intellectual property (IP) regime and new free trade agreements (FTAs) currently under discussion in India could endanger that country's role as the "pharmacy of the developing world", especially for HIV/AIDS medicines, wiping out the gains in antiretroviral treatment made over the past few years, suggests a new study.